Featured Research

from universities, journals, and other organizations

Biosimilar CT-P13 matches infliximab in improving ankylosing spondylitis disease activity

Date:
June 11, 2014
Source:
European League Against Rheumatism
Summary:
New data show that the newly approved infliximab biosimilar CT-P13 achieves statistically similar improvements in disease activity, disability and mobility in patients with ankylosing spondylitis compared to its original reference product infliximab.

ew data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) show that the newly-approved infliximab biosimilar CT-P13 achieves statistically similar improvements in disease activity, disability and mobility in patients with Ankylosing Spondylitis (AS) compared to its original reference product infliximab (INX).

CT-P13 is the world's first biosimilar monoclonal antibody to receive a positive opinion from an advanced and developed nations' regulatory body. According to Dr Won Park, Inha University Hospital, Korea, and lead investigator of the PLANETAS study, "the challenge for biosimilars is to demonstrate similarity in therapeutic effectiveness, safety and immunogenicity to their reference product, not just biochemical and pharmacokinetic equivalence."

"By demonstrating comparable efficacy and safety, the results of our clinical trials should give physicians confidence in using CT-P13 as an alternative treatment option to INX in AS patients," Dr Park added. "This is good news for patients who may previously have had limited access to costly antibody biopharmaceuticals."

AS is a type of chronic arthritis affecting an estimated 1.4 million patients in Europe. In AS, inflammation in the joints and ligaments causes pain and stiffness in the neck, back and buttocks. The cause of AS is unknown, and there is no known cure, so the current aim of treatment is to reduce pain and stiffness and to keep the spine flexible.

These new data captured clinical measures of disease activity via ASAS20/40 and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), disability via the Bath Ankylosing Spondylitis Functional Index (BASFI) and mobility via the Bath Ankylosing Spondylitis Metrology Index (BASMI). In addition, the Student's t test was used to compare mean change of three indices from baseline in both treatment groups.

At week 54, BASDAI improved significantly from baseline in both treatment groups (CT-P13: from 6.74 to 3.78 and INX: from 6.57 to 3.70) and this improvement was similar between groups (difference of means -0.29; CI of the difference -0.91 to 0.32). BASFI and BASMI were also similarly improved: BASFI (CT-P13: from 6.20 to 3.42 and INX: from 6.24 to 3.46) and BASMI (CT-P13: from 4.0 to 2.8 and INX: from 4.1 to 3.2).

In addition, a 50% improvement of the baseline BASDAI (BASDAI50) was achieved in 44.3% for CT-P13 and 46.3% for INX at week 54; the BASDAI50 response rate was comparable between the two groups (p=0.7737).

A second objective of the study was to assess the effect of anti-drug antibody (ADA) on clinical outcomes. The use of biological agents can cause the production of ADA leading to reduced levels of treatment in the blood, impacting treatment response and/or increasing rates of infusion reaction. In the study, the presence of ADA was measured using electrochemiluminescent methodology and clinical responses in all treatment groups were examined in relation to the presence of ADA. Higher ASAS20/40 responses were seen in the ADA negative patients (72.7%/56.5%) compared with ADA positive patients (54.7%/37.7%) at week 54.

The BASDAI and BASFI improved significantly in the ADA negative subgroup compared to the ADA positive subgroup (BASDAI: -3.13 vs. -2.30 and BASFI: -2.97 vs. -2.18), but no clear association with ADA was seen for BASMI. A greater clinical response was shown in the ADA negative subgroup in all three indices. However, the incidence of the ADA and their magnitude of impact on the clinical response or adverse event were similar between biosimilar CT-P13 and innovator infliximab.

CT-P13 has previously demonstrated pharmacokinetic (PK) equivalence to INX in the PLANETAS trial, a randomised double-blind, parallel group study of 250 patients with AS, and was recently approved by the European Medicines Agency.


Story Source:

The above story is based on materials provided by European League Against Rheumatism. Note: Materials may be edited for content and length.


Cite This Page:

European League Against Rheumatism. "Biosimilar CT-P13 matches infliximab in improving ankylosing spondylitis disease activity." ScienceDaily. ScienceDaily, 11 June 2014. <www.sciencedaily.com/releases/2014/06/140611093713.htm>.
European League Against Rheumatism. (2014, June 11). Biosimilar CT-P13 matches infliximab in improving ankylosing spondylitis disease activity. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/2014/06/140611093713.htm
European League Against Rheumatism. "Biosimilar CT-P13 matches infliximab in improving ankylosing spondylitis disease activity." ScienceDaily. www.sciencedaily.com/releases/2014/06/140611093713.htm (accessed August 1, 2014).

Share This




More Health & Medicine News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Quintuplets Head Home

Texas Quintuplets Head Home

Reuters - US Online Video (Aug. 1, 2014) After four months in the hospital, the first quintuplets to be born at Baylor University Medical Center head home. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Patient Coming to U.S. for Treatment

Ebola Patient Coming to U.S. for Treatment

Reuters - US Online Video (Aug. 1, 2014) A U.S. aid worker infected with Ebola while working in West Africa will be treated in a high security ward at Emory University in Atlanta. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Vaccine Might Be Coming, But Where's It Been?

Ebola Vaccine Might Be Coming, But Where's It Been?

Newsy (Aug. 1, 2014) Health officials are working to fast-track a vaccine — the West-African Ebola outbreak has killed more than 700. But why didn't we already have one? Video provided by Newsy
Powered by NewsLook.com
Study Links Certain Birth Control Pills To Breast Cancer

Study Links Certain Birth Control Pills To Breast Cancer

Newsy (Aug. 1, 2014) Previous studies have made the link between birth control and breast cancer, but the latest makes the link to high-estrogen oral contraceptives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins